Home / M&A Activity / McAleese & Associates: L3, Harris to Spend 4% of Combined Sales on Independent R&D

McAleese & Associates: L3, Harris to Spend 4% of Combined Sales on Independent R&D

Jim McAleese

A McAleese & Associates report says the merged company of L3 Technologies (NYSE: LLL) and Harris (NYSE: HRS) would invest 4 percent of $18B combined revenue in independent research-and-development efforts.

Defense News reported Monday that focus areas of the proposed IRAD investment are actionable intelligence, spectrum superiority and warfighter effectiveness.

Jim McAleese, founder and principal at McAleese & Associates and a 2019 Wash100 winner, noted Harris and L3 plan to divest a significant portion of lower value operations within the first six months after the merger’s completion.

The two companies also have agreed to firewalls on the U.S. Navy’s Next Generation Jammer Increment II program and expect to complete the merger by the end of June, McAleese noted.

L3 and Harris agreed to merge through an all-stock transaction in October to establish a global defense technology firm that will operate as L3 Harris Technologies.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.